These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 18811804)

  • 1. Circadian rhythm of appropriate implantable cardioverter defibrillator discharges in patients with hypertrophic cardiomyopathy.
    Kiernan TJ; Weivoda PL; Somers VK; Ommen SR; Gersh BJ
    Pacing Clin Electrophysiol; 2008 Oct; 31(10):1253-8. PubMed ID: 18811804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy.
    McLeod CJ; Ommen SR; Ackerman MJ; Weivoda PL; Shen WK; Dearani JA; Schaff HV; Tajik AJ; Gersh BJ
    Eur Heart J; 2007 Nov; 28(21):2583-8. PubMed ID: 17483110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy.
    Cuoco FA; Spencer WH; Fernandes VL; Nielsen CD; Nagueh S; Sturdivant JL; Leman RB; Wharton JM; Gold MR
    J Am Coll Cardiol; 2008 Nov; 52(21):1718-23. PubMed ID: 19007692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
    Noseworthy PA; Rosenberg MA; Fifer MA; Palacios IF; Lowry PA; Ruskin JN; Sanborn DM; Picard MH; Vlahakes GJ; Mela T; Das S
    Am J Cardiol; 2009 Jul; 104(1):128-32. PubMed ID: 19576333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy.
    Lin G; Nishimura RA; Gersh BJ; Phil D; Ommen SR; Ackerman MJ; Brady PA
    Heart; 2009 May; 95(9):709-14. PubMed ID: 19282314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of implantable defibrillator discharges in high-risk patients with hypertrophic cardiomyopathy.
    Woo A; Monakier D; Harris L; Hill A; Shah P; Wigle ED; Rakowski H; Rozenblyum E; Cameron DA
    Heart; 2007 Sep; 93(9):1044-5. PubMed ID: 17699173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy.
    Maron BJ; Spirito P
    J Cardiovasc Electrophysiol; 2008 Oct; 19(10):1118-26. PubMed ID: 18384577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcoronary ablation of septal hypertrophy does not alter ICD intervention rates in high risk patients with hypertrophic obstructive cardiomyopathy.
    Lawrenz T; Obergassel L; Lieder F; Leuner C; Strunk-Mueller C; Meyer Zu Vilsendorf D; Beer G; Kuhn H
    Pacing Clin Electrophysiol; 2005 Apr; 28(4):295-300. PubMed ID: 15826262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolongation of the QTc interval predicts appropriate implantable cardioverter-defibrillator therapies in hypertrophic cardiomyopathy.
    Gray B; Ingles J; Medi C; Semsarian C
    JACC Heart Fail; 2013 Apr; 1(2):149-55. PubMed ID: 24621839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Septal myectomy after failed alcohol ablation: Does previous percutaneous intervention compromise outcomes of myectomy?
    Quintana E; Sabate-Rotes A; Maleszewski JJ; Ommen SR; Nishimura RA; Dearani JA; Schaff HV
    J Thorac Cardiovasc Surg; 2015 Jul; 150(1):159-67.e1. PubMed ID: 25940414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circadian patterns in the occurrence of malignant ventricular tachyarrhythmias triggering defibrillator interventions in patients with hypertrophic cardiomyopathy.
    Maron BJ; Semsarian C; Shen WK; Link MS; Epstein AE; Estes NA; Almquist A; Giudici MC; Haas TS; Hodges JS; Spirito P
    Heart Rhythm; 2009 May; 6(5):599-602. PubMed ID: 19332391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ST-segment depression as a risk factor in hypertrophic cardiomyopathy.
    Haghjoo M; Mohammadzadeh S; Taherpour M; Faghfurian B; Fazelifar AF; Alizadeh A; Rad MA; Sadr-Ameli MA
    Europace; 2009 May; 11(5):643-9. PubMed ID: 19164362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
    Sorajja P; Valeti U; Nishimura RA; Ommen SR; Rihal CS; Gersh BJ; Hodge DO; Schaff HV; Holmes DR
    Circulation; 2008 Jul; 118(2):131-9. PubMed ID: 18591440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temporal relationship of implantable cardioverter defibrillator discharges and environmental physical activity.
    Stoupel E; Kusniec J; Mazur A; Zabarsky R; Golovchiner G; Abramson E; Strasberg B; Battler A
    Pacing Clin Electrophysiol; 2005 Aug; 28(8):777-81. PubMed ID: 16105003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Ventricular tachyarrhythmias in patients with cardiomyopathy].
    Henningsen K; Christensen AH; Svendsen JH
    Ugeskr Laeger; 2008 Jun; 170(25):2238-42. PubMed ID: 18565313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circadian pattern of spontaneous ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators.
    Eksik A; Akyol A; Norgaz T; Aksu H; Erdinler I; Cakmak N; Alper AT; Cinar B; Yildirim A; Gürkan K
    Med Sci Monit; 2007 Sep; 13(9):CR412-416. PubMed ID: 17767121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circadian, daily, and seasonal distributions of ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillators.
    Anand K; Aryana A; Cloutier D; Hee T; Esterbrooks D; Mooss AN; Mohiuddin SM
    Am J Cardiol; 2007 Oct; 100(7):1134-8. PubMed ID: 17884377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversed circadian rhythms of heart rate variability and morning peak occurrence of sustained ventricular tachyarrhythmias in patients with implanted cardioverter defibrillator.
    Fries R; Hein S; K nig J
    Med Sci Monit; 2002 Nov; 8(11):CR751-6. PubMed ID: 12444379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy.
    Jayatilleke I; Doolan A; Ingles J; McGuire M; Booth V; Richmond DR; Semsarian C
    Am J Cardiol; 2004 May; 93(9):1192-4. PubMed ID: 15110224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Posttraumatic stress symptoms and predicted mortality in patients with implantable cardioverter-defibrillators: results from the prospective living with an implanted cardioverter-defibrillator study.
    Ladwig KH; Baumert J; Marten-Mittag B; Kolb C; Zrenner B; Schmitt C
    Arch Gen Psychiatry; 2008 Nov; 65(11):1324-30. PubMed ID: 18981344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.